| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6559183 | BIOFRONTERA | Nano-emulsion of 5-aminolevulinic acid |
Nov, 2019
(4 years ago) | |
| US11540981 | BIOFRONTERA | Nanoemulsion formulation with improved stability and cell penetration |
Feb, 2028
(3 years from now) | |
| US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(16 years from now) | |
Ameluz is owned by Biofrontera.
Ameluz contains Aminolevulinic Acid Hydrochloride.
Ameluz has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Ameluz are:
- US6559183
Ameluz was authorised for market use on 10 May, 2016.
Ameluz is available in gel;topical dosage forms.
Ameluz can be used as topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light, treatment of actinic keratoses by photodynamic therapy.
The generics of Ameluz are possible to be released after 15 October, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 10, 2019 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 10 May, 2016
Treatment: Treatment of actinic keratoses by photodynamic therapy; Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illu...
Dosage: GEL;TOPICAL
AMELUZ family patents
